Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464827 · ClinicalTrials.gov registry record · Phase 2
ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 580
- Enrollment target
NCT01464827: Completed Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
NCT01464827 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 580 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (336% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01464827, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 580 participants
- Enrollment target
Study Summary
This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin (RBV) in patients with chronic Hepatitis C Virus (HCV).
Primary Outcome
An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each AE to the use of direct-acting antiviral agents (DAAs) and to ribavirin, and rated the severity of each event as either: Mild: The AE was transient and easily tolerated by the participant; Moderate: The AE caused the
Interventions
- DRUG Ritonavir
- DRUG Ribavirin
- DRUG ABT-450
- DRUG ABT-333
- DRUG ABT-267
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT01464827 record still lists
NCT01464827 is an interventional study that assigns participants to a tested intervention. The registered 580 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (336% higher).
The record links to 0 conditions, and to 5 interventions - of which Ritonavir is the first listed.
NCT01464827 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01464827 about?
NCT01464827 is a clinical study titled "ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients". This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin (RBV) in patients with chronic Hepatitis C Virus (HCV).
What is the current status of trial NCT01464827?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 580 participants. The study started on 2011-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01464827?
The interventions under investigation include: Ritonavir (DRUG), Ribavirin (DRUG), ABT-450 (DRUG), ABT-333 (DRUG), ABT-267 (DRUG).
Who is sponsoring clinical trial NCT01464827?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01464827's enrollment target sits among peer trials
580 58th of 2000 higher than 1,942 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia